LivaNova PLC
185 articles about LivaNova PLC
-
LivaNova Announces One-Millionth Inspire Adult Oxygenator Patient
4/26/2018
LivaNova PLC announced its Inspire® innovative adult oxygenator system has treated its one-millionth patient.
-
LivaNova Announces Enrollment for PERFECT Perceval Valve Clinical Trial in China
3/22/2018
LivaNova PLC has announced the first patient enrollment in the Perceval® Valve Clinical study for Chinese Registration (“PERFECT”) Trial.
-
LivaNova Enters into Definitive Agreement to Divest Its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation
3/8/2018
LivaNova PLC announced that it has entered into a definitive Stock and Asset Purchase Agreement to divest its Cardiac Rhythm Management business franchise to MicroPort Scientific Corporation.
-
LivaNova Reports Fourth Quarter and Full-Year 2017 Results
2/28/2018
For the fourth quarter of 2017, worldwide sales from continuing operations were $278.4 million, an increase of 11.5 percent on a reported basis and an increase of 8.1 percent on a constant currency basis, as compared to the same quarter of the previous year.
-
Company will add advanced cardiopulmonary temporary support solutions to its portfolio.
-
The phthalate (DEHP)-free flexible tubing features exceptional transparency and a wire-reinforcement spring to deliver flexibility without kinking.
-
LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2017 Results
1/24/2018
LivaNova will host a conference call to discuss its fourth quarter and full-year 2017 results on Wednesday, Feb. 28, 2018 at 8 a.m. CST (2 p.m. GMT).
-
LivaNova Initiates BELIEVE Aortic Heart Valve Study in the U.S. and Canada
1/11/2018
This study is a post-market, prospective, interventional, multi-center trial designed to report the overall incidence of reduced leaflet motion identified by CT imaging in patients receiving a commercially approved LivaNova bioprosthetic aortic heart valve.
-
LivaNova Announces Matthew J. Dodds as Senior Vice President, Corporate Development
1/8/2018
In this role, Dodds is responsible for Business Development, Investor Relations and Corporate Communications.
-
LivaNova Commences Global RESTORE-LIFE Study for Treatment-Resistant Depression
1/4/2018
LivaNova today announced the launch and enrollment of the first patient in the Global Prospective, Multi-center, Observational Post-market Study to Assess Short-, Mid- and Long-term Effectiveness and Efficiency of Vagus Nerve
-
A look at three of the best performing medtech stocks out there right now.
-
LivaNova will enter obstructive sleep apnea space, enhancing its portfolio of Neuromodulation treatments and therapies.
-
The CRM Business Franchise develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failures.
-
LivaNova Reports Third Quarter 2017 Results
11/3/2017
For the third quarter of 2017, worldwide sales were $309.7 million, an increase of 4.9 percent on a reported basis and an increase of 3.1 percent on a constant currency basis, as compared to the same quarter of the previous year.
-
LivaNova Recognizes Epilepsy Awareness Month This November
11/2/2017
The need for awareness, treatment options and education is at an all-time high.
-
LivaNova Gets FDA OK for SenTiva Device and Next-Generation Epilepsy Programming System
10/9/2017
-
LivaNova Announces One-Millionth Patient Treated With Advanced XTRA Autotransfusion System
10/2/2017
-
LivaNova To Host Conference Call For Third Quarter 2017 Results
9/28/2017
-
LivaNova And MicroPort Scientific Announce The Approval Of Rega Pacemakers By The China Food And Drug Administration
9/28/2017
-
LivaNova And MicroPort Scientific Announce The Approval Of Rega Pacemakers By The China Food And Drug Administration
9/27/2017